Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Northwest University, 229 Taibai North Road, Xi'an, Shaanxi Province 710069, People's Republic of China.
Shaanxi Key Laboratory of Degradable Biomedical Materials; Shaanxi R&D Center of Biomaterial and Fermentation Engineering, School of Chemical Engineering, Northwest University, 229 TaiBai North Road, Xi'an, Shaanxi Province 710069, People's Republic of China.
Biomed Mater. 2020 Dec 12;16(1):012001. doi: 10.1088/1748-605X/aba6fa.
Natural animal collagen and its recombinant collagen are favourable replacements in human tissue engineering due to their remarkable biomedical property. However, this exploitation is largely restricted due to the potential of immunogenicity and virus contamination. Exploring new ways to produce human collagen is fundamental to its biomedical and clinical application. All human fibrillar collagen molecules have three polypeptide chains constructed from a repeating Gly-Xaa-Yaa triplet, where Xaa and Yaa represent one random amino acid. Using cDNA techniques to modify several repeat sequences of the cDNA fragment, a novel human collagen, named recombinant human-like collagen (rHLC), with low immunogenicity and little risk from hidden virus can be engineered and notably tailored to specific applications. Human-like collagen (HLC) was initially used as a coating to modify the tissue engineering scaffold, and then used as the scaffold after cross-link agents were added to increase its mechanical strength. Due to its good biocompatibility, low immunogenicity, stabilised property, and the ability of mass production, HLC has been widely used in skin injury treatments, vascular scaffolds engineering, cartilage, bone defect repair, skincare, haemostatic sponge, and drug delivery, including coating with medical nanoparticles. In this review, we symmetrically reviewed the development, recent advances in design and application of HLC, and other recombinant human collagen-based biomedicine potentials. At the end, future improvements are also discussed.
天然动物胶原蛋白及其重组胶原蛋白因其出色的生物医学特性，成为人类组织工程中理想的替代品。然而，由于其免疫原性和病毒污染的潜在风险，这种应用在很大程度上受到限制。探索生产人类胶原蛋白的新方法对于其生物医学和临床应用至关重要。所有人类纤维状胶原蛋白分子都由三个多肽链组成，这些多肽链由重复的 Gly-Xaa-Yaa 三肽构成，其中 Xaa 和 Yaa 代表一种随机氨基酸。利用 cDNA 技术修饰 cDNA 片段的几个重复序列，可以设计出一种新型的低免疫原性和低病毒风险的重组人类样胶原蛋白（rHLC），并可根据特定应用进行定制。人类样胶原蛋白（HLC）最初被用作修饰组织工程支架的涂层，然后在添加交联剂以增加其机械强度后用作支架。由于其良好的生物相容性、低免疫原性、稳定的特性和大规模生产的能力，HLC 已广泛应用于皮肤损伤治疗、血管支架工程、软骨、骨缺损修复、皮肤护理、止血海绵和药物输送，包括与医用纳米颗粒的涂层。在这篇综述中，我们对称地回顾了 HLC 的发展、设计和应用的最新进展以及其他基于重组人类胶原蛋白的生物医学潜力。最后，还讨论了未来的改进。
